Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

GSK’s Breo Ellipta: FDA Panel To Weigh Large Safety Study For Asthma Claim

Feb 11 2015

• By Sarah Karlin-Smith

Related Content

GSK’s <em>Breo Ellipta</em> Marches Forward For Asthma, Efficacy Undistinguished From <em>Advair</em>

Jun 30 2014

Mini-Sentinel Project Will Evaluate Impact Of LABA Label Change

Sep 26 2011

GSK Reveals Big Changes As 2015 Growth Prospects Fizzle

Oct 27 2014

FDA Calls For Class-Wide REMS For LABA Asthma Drugs

Feb 22 2010

At Liraglutide Panel Review, A Call For CV Studies To Look Beyond MACE

Sep 22 2014

GSK’s <em>Breo Ellipta</em> Approved With COPD Airflow Obstruction, Exacerbation Claims

May 10 2013

Related Companies

GSK plc

AstraZeneca PLC

Merck & Co., Inc.

Novartis AG

Additional Topics

United States Clinical Trials Regulation Advisory Committees BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window